通脉化浊汤治疗痰瘀互结型高血压病的效果及对转化生长因子β1、血管内皮生长因子、可溶性细胞间黏附分子-1的影响

摘要

Objective To investigate the effect of Tongmai Huazhuo Decoction in the treatment of hypertension patients with syndrome of intermin-gled phlegm and blood stasis and its influence on transforming growth factor-β1 (TGF-β1),vascular endothelial growth factor (VEGF),soluble intercellular adhesion molecule-1 (sICAM-1).Methods Seventy hypertension patients with syndrome of intermin-gled phlegm and blood stasis admitted to the Second Department of Cardiology,the Second Hospital Affiliated to Liaoning University of Traditional Chinese Medicine from August 2013 to July 2016 were selected and randomly divided into experimental group and control group,with 35 cases in each group.The control group was treated with Amlodipine Besylate 5 mg,one agent every day.On basis of control group,the experimental group was treated with Chinese medicine Tongmai Huazhuo Decoction,once a day.The course of the two groups was 8 weeks.The clinical efficacy and levels of blood pressure,TGF-β1,VEGF,sICAM-1 before and after treatment between the two groups were compared.Results The total effective rate in the experimental group was higher than that of control group,the difference was statistically significant (P ＜ 0.05).After treatment,the levels of systolic blood pressure and diastolic blood pressure in the two groups were all lower than those before treatment,and the levels of systolic blood pressure and diastolic blood pressure in the experimental group after treatment were lower than those of control group,the differences were statistically significant (P ＜ 0.05).After treatment,the levels of TGF-β1,VEGF and sICAM-1 in the two groups were all lower than those before treatment,and the levels of TGF-β1,VEGF and sICAM-1 in the experimental group after treatment were lower than those of control group,the differences were statistically significant (P ＜ 0.05).Conclusion Tongmai Huazhuo Decoction in the treatment of hypertension patients with syndrome of intermin-gled phlegm and blood stasis has significant curative effects,which can down-regulate the levels of TGF-β1,VEGF and sICAM-1,it is suitable for clinical promotion and application.%目的 探讨通脉化浊汤治疗痰瘀互结型高血压病的效果及对转化生长因子β1(TGF-β1)、血管内皮生长因子(VEGF)、可溶性细胞间黏附分子-1(sICAM-1)的影响.方法 收集辽宁中医药大学附属第二医院心内二科2013年8月～2016年7月收治的70例痰瘀互结型高血压病患者,将其随机分为试验组和对照组,各35例.对照组予以苯磺酸氨氯地平片5 mg口服,每日1次.试验组在对照组的基础上予以中药汤剂通脉化浊汤,每日1剂,两组疗程均为8周.比较两组患者临床疗效和治疗前后的血压、TGF-β1、VEGF、sICAM-1水平.结果 试验组总有效率明显高于对照组,差异有统计学意义(P＜0.05).治疗后,两组患者收缩压、舒张压水平均明显低于治疗前,且试验组治疗后收缩压、舒张压水平明显低于对照组,差异有统计学意义(P＜0.05).治疗后,两组患者TGF-β1、VEGF、sICAM-1水平均较治疗前显著降低,且试验组治疗后TGF-β1、VEGF、sICA M-1水平明显低于对照组,差异有统计学意义(P＜0.05).结论 通脉化浊汤治疗痰瘀互结型高血压病临床效果显著,其能下调TGF-β1、VEGF、sICAM-1水平,适宜临床推广应用.